70 related articles for article (PubMed ID: 35347237)
21. A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Chen Y; Zhao H; Luo J; Liao Y; Dan X; Hu G; Gu W
Front Oncol; 2022; 12():944511. PubMed ID: 36439517
[TBL] [Abstract][Full Text] [Related]
22. Management of Peripheral T-cell Lymphomas and the Role of Transplant.
Foley NC; Mehta-Shah N
Curr Oncol Rep; 2022 Nov; 24(11):1489-1499. PubMed ID: 35947286
[TBL] [Abstract][Full Text] [Related]
23. IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment.
Leca J; Lemonnier F; Meydan C; Foox J; El Ghamrasni S; Mboumba DL; Duncan GS; Fortin J; Sakamoto T; Tobin C; Hodgson K; Haight J; Smith LK; Elia AJ; Butler D; Berger T; de Leval L; Mason CE; Melnick A; Gaulard P; Mak TW
Cancer Cell; 2023 Feb; 41(2):323-339.e10. PubMed ID: 36736318
[TBL] [Abstract][Full Text] [Related]
24. Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study.
Kim WS; Fukuhara N; Yoon DH; Yamamoto K; Uchida T; Negoro E; Izutsu K; Terui Y; Nakajima H; Ando K; Suehiro Y; Kang HJ; Ko PS; Nagahama F; Sonehara Y; Nagai H; Tien HF; Kwong YL; Tobinai K
Blood Adv; 2023 Sep; 7(17):4903-4912. PubMed ID: 36661315
[TBL] [Abstract][Full Text] [Related]
25. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Rai S; Kim WS; Ando K; Choi I; Izutsu K; Tsukamoto N; Yokoyama M; Tsukasaki K; Kuroda J; Ando J; Hidaka M; Koh Y; Shibayama H; Uchida T; Yang DH; Ishitsuka K; Ishizawa K; Kim JS; Lee HG; Minami H; Eom HS; Kurosawa M; Lee JH; Lee JS; Lee WS; Nagai H; Shindo T; Yoon DH; Yoshida S; Gillings M; Onogi H; Tobinai K
Haematologica; 2023 Mar; 108(3):811-821. PubMed ID: 36200417
[TBL] [Abstract][Full Text] [Related]
26. Multisystem inflammatory syndrome in children in Singapore.
Nadua KD; Chong CY; Kam KQ; Mok YH; Choo JTL; Lam JCM; Li J; Tan NWH; Yung CF; Chan SWB; Teh KL; Das L; Arkachaisri T; Thoon KC
Ann Acad Med Singap; 2022 Nov; 51(11):669-676. PubMed ID: 36453214
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis.
Shafagati N; Koh MJ; Boussi L; Park HJ; Stuver R; Bain P; Foss FM; Shen C; Jain S
Blood Adv; 2022 Aug; 6(16):4740-4762. PubMed ID: 35816645
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics and treatments of multi-system inflammatory syndrome in children: a systematic review.
Lee KH; Li H; Lee MH; Park SJ; Kim JS; Han YJ; Cho K; Ha B; Kim SJ; Jacob L; Koyanagi A; Shin JI; Kim JH; Smith L
Eur Rev Med Pharmacol Sci; 2022 May; 26(9):3342-3350. PubMed ID: 35587087
[TBL] [Abstract][Full Text] [Related]
29. Current Treatment of Peripheral T-cell Lymphoma.
Stuver R; Epstein-Peterson ZD; Johnson WT; Khan N; Lewis N; Moskowitz AJ; Sauter CS; Horwitz S
Oncology (Williston Park); 2022 May; 36(5):293-305. PubMed ID: 35576176
[TBL] [Abstract][Full Text] [Related]
30. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study.
Brink M; Meeuwes FO; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer LH; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Plattel W; Huls GA; Vermaat JSP; Nijland M
Blood; 2022 Sep; 140(9):1009-1019. PubMed ID: 35544601
[TBL] [Abstract][Full Text] [Related]
31. Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma.
Zhang Q; Yin L; Lai Q; Zhao Y; Peng H
Clin Exp Med; 2023 Dec; 23(8):4219-4235. PubMed ID: 37759042
[TBL] [Abstract][Full Text] [Related]
32. Hemophagocytic lymphohistiocytosis after autologous stem cell transplantation in angioimmunoblastic T-cell lymphoma: A case report.
Zhang ZR; Dou AX; Liu Y; Zhu HB; Jia HP; Kong QH; Sun LK; Qin AQ
World J Clin Cases; 2023 Jun; 11(17):4072-4078. PubMed ID: 37388798
[TBL] [Abstract][Full Text] [Related]
33. PTCL, NOS: An update on classification, risk-stratification, and treatment.
Weiss J; Reneau J; Wilcox RA
Front Oncol; 2023; 13():1101441. PubMed ID: 36845711
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma.
Stuver R; Moskowitz AJ
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765544
[TBL] [Abstract][Full Text] [Related]
35. Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare?
Assi R; Salman H
Cells; 2022 Dec; 11(24):. PubMed ID: 36552738
[TBL] [Abstract][Full Text] [Related]
36. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.
Kameda K; Kako S; Kim SW; Usui Y; Kato K; Fukuda T; Uchida N; Kobayashi H; Wakayama T; Sakaida E; Yano S; Imada K; Nara M; Ikeda T; Fuchida SI; Ishikawa J; Sugahara H; Kanda J; Kimura T; Ichinohe T; Atsuta Y; Kondo E
Leukemia; 2022 May; 36(5):1361-1370. PubMed ID: 35347237
[TBL] [Abstract][Full Text] [Related]
37. Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma - The Oregon Health and Science University Experience.
Galligan D; Williamson S; Myers J; Chen AI; Hayes-Lattin B; Okada C; Spurgeon S; Maziarz R; Schachter L
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):874-881. PubMed ID: 37741763
[TBL] [Abstract][Full Text] [Related]
38. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
39. Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma.
Yamasaki S; Yoshida S; Kato K; Choi I; Imamura Y; Kohno K; Henzan H; Tanimoto K; Ogawa R; Suehiro Y; Miyamoto T; Eto T; Ohshima K; Akashi K; Iwasaki H;
Int J Hematol; 2020 Jul; 112(1):74-83. PubMed ID: 32297159
[TBL] [Abstract][Full Text] [Related]
40. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
